Duopharma Biotech Bhd
KLSE:DPHARMA
Net Margin
Duopharma Biotech Bhd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
MY |
D
|
Duopharma Biotech Bhd
KLSE:DPHARMA
|
1.2B MYR |
7%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
783.4B USD |
24%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
389.2B USD |
16%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
233.7B CHF |
20%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
174.1B GBP |
13%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
223.1B USD |
27%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
198.6B CHF |
23%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
142.8B USD |
13%
|
Duopharma Biotech Bhd
Glance View
Duopharma Biotech Bhd.is an investment holding company, which engages in the manufacturing and distribution of pharmaceutical products. The company is headquartered in Klang, Selangor. The company went IPO on 2002-07-18. The Company, through its subsidiaries is engaged in manufacturing, distribution, importing and exporting of pharmaceutical products and medicines. The firm also engaged in research and development of pharmaceutical products. Its subsidiaries include Duopharma (M) Sendirian Berhad, Duopharma Manufacturing (Bangi) Sdn. Bhd., Duopharma Marketing Sdn. Bhd., Duopharma Consumer Healthcare Sdn. Bhd., Duopharma HAPI Sdn. Bhd., Duopharma Innovation Sdn. Bhd., Unique Pharmacy (Penang) Sdn. Bhd., Sentosa Pharmacy Sdn. Bhd., Duopharma Manufacturing (Glenmarie) Sdn. Bhd., Negeri Pharmacy Sdn. Bhd., Duopharma (Singapore) Pte. Ltd. and DB (Philippines), Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Duopharma Biotech Bhd's most recent financial statements, the company has Net Margin of 7.1%.